- Home
- HHH vs TGTX Comparison
HHH vs TGTX Comparison
Compare HHH & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHH
- TGTX
- Stock Information
- Founded
- HHH 2010
- TGTX 1993
- Country
- HHH United States
- TGTX United States
- Employees
- HHH N/A
- TGTX N/A
- Industry
- HHH Real Estate Investment Trusts
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- HHH Real Estate
- TGTX Health Care
- Exchange
- HHH Nasdaq
- TGTX Nasdaq
- Market Cap
- HHH 4.7B
- TGTX 5.5B
- IPO Year
- HHH N/A
- TGTX 1995
- Fundamental
- Price
- HHH $85.69
- TGTX $30.92
- Analyst Decision
- HHH Buy
- TGTX Strong Buy
- Analyst Count
- HHH 2
- TGTX 5
- Target Price
- HHH $90.00
- TGTX $48.20
- AVG Volume (30 Days)
- HHH 330.4K
- TGTX 2.1M
- Earning Date
- HHH 11-10-2025
- TGTX 11-03-2025
- Dividend Yield
- HHH N/A
- TGTX N/A
- EPS Growth
- HHH 234.52
- TGTX N/A
- EPS
- HHH 5.10
- TGTX 2.78
- Revenue
- HHH $1,834,033,000.00
- TGTX $531,898,000.00
- Revenue This Year
- HHH N/A
- TGTX $82.31
- Revenue Next Year
- HHH $21.07
- TGTX $49.05
- P/E Ratio
- HHH $16.47
- TGTX $11.17
- Revenue Growth
- HHH 69.81
- TGTX 100.88
- 52 Week Low
- HHH $61.41
- TGTX $25.28
- 52 Week High
- HHH $90.27
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- HHH 60.30
- TGTX 36.81
- Support Level
- HHH $78.00
- TGTX $29.80
- Resistance Level
- HHH $90.27
- TGTX $31.78
- Average True Range (ATR)
- HHH 1.99
- TGTX 1.75
- MACD
- HHH 0.79
- TGTX -0.40
- Stochastic Oscillator
- HHH 63.80
- TGTX 16.79
About HHH Howard Hughes Holdings Inc.
Howard Hughes Holdings Inc owns, manages, and develops commercial, residential, and mixed-use real estate throughout the USA. Its portfolio is strategically positioned to meet and accelerate development based on market demand, resulting in one of the strongest real estate platforms in the country. It operates through four business segments: Operating Assets, MPCs, Strategic Developments and Seaport.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.